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AbstrACt
Objectives To assess the effects of botulinum toxin for 
prevention of migraine in adults.
Design Systematic review and meta-analysis.
Data sources CENTRAL, MEDLINE, Embase and trial 
registries.
Eligibility criteria We included randomised controlled 
trials (RCTs) of botulinum toxin compared with placebo, 
active treatment or clinically relevant different dose for 
adults with chronic or episodic migraine, with or without 
the additional diagnosis of medication overuse headache.
Data extraction and synthesis Cochrane methods were 
used to review double-blind RCTs. Twelve week post-
treatment time-point data was analysed.
results Twenty-eight trials (n=4190) were included. Trial 
quality was mixed. Botulinum toxin treatment resulted in 
reduced frequency of −2.0 migraine days/month (95% CI 
−2.8 to −1.1, n=1384) in chronic migraineurs compared 
with placebo. An improvement was seen in migraine 
severity, measured on a numerical rating scale 0 to 10 
with 10 being maximal pain, of −2.70 cm (95% CI −3.31 
to −2.09, n=75) and −4.9 cm (95% CI −6.56 to −3.24, 
n=32) for chronic and episodic migraine respectively. 
Botulinum toxin had a relative risk of treatment related 
adverse events twice that of placebo, but a reduced risk 
compared with active comparators (relative risk 0.76, 95% 
CI 0.59 to 0.98) and a low withdrawal rate (3%). Although 
individual trials reported non-inferiority to oral treatments, 
insufficient data were available for meta-analysis of 
effectiveness outcomes.
Conclusions In chronic migraine, botulinum toxin reduces 
migraine frequency by 2 days/month and has a favourable 
safety profile. Inclusion of medication overuse headache 
does not preclude its effectiveness. Evidence to support or 
refute efficacy in episodic migraine was not identified.
IntrODuCtIOn
Migraine is the seventh leading cause of years 
lived with disability globally and is estimated 
to affect around 15% of the world’s popula-
tion.1 Days lost from work and other activities 
of daily living resulting from migraines have 
a major economical impact.2 Many people 
with migraine suffer prolonged and frequent 
migraine attacks despite optimised acute and 
prophylactic treatments.3–5 
Botulinum toxin type A (BTX-A) has been 
licensed for use in migraine in some countries, 
based largely on two commercially sponsored 
trials.6 7 The recommended reconstituted 
dose is 155 to 195 units, administered intra-
muscularly as 0.1 mL (five units) injections to 
between 31 and 39 sites around the head and 
neck.3 Cost of treatment and administration 
of BTX-A is much higher than standard doses 
of the two first line treatments for the preven-
tion of migraine, propranolol and topiramate 
(around 25 times and 15 times respectively in 
the UK).8–10
Migraine can be categorised as chronic 
or episodic and these terms are commonly 
used in eligibility criteria for clinical trials 
and systematic reviews. Chronic migraine is 
currently defined by the International Head-
ache Society (IHS) as headache for at least 
15 days per month with migraine features 
on eight of those days.11 Episodic migraine 
is commonly used to describe patients with 
symptoms of migraine who have less than 15 
headache days per month and according to 
official guidance is a term which can be used 
for migraine that is not covered by the defi-
nition of chronic migraine.11 Migraine can 
occur with medication overuse headache; the 
strengths and limitations of this study
 ► This paper is a summary of a Cochrane review con-
ducted using systematic and thorough methodology 
to identify and synthesise all available evidence for 
the effectiveness of botulinum toxin for prophylactic 
treatment of migraine.
 ► No language or date restrictions were placed on the 
search strategy.
 ► Many of the included studies were small in size and 
failed to fully report their data which impacted the 
quality ratings and the content of the meta-analyses.
 ► Our chosen primary outcome measure, though rec-
ommended in current guidelines for controlled trials 
of prophylactic treatment of chronic migraine, was 
not commonly recorded.
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IHS definition has evolved, but currently this is defined 
as an interaction between a therapeutic agent used exces-
sively and a susceptible patient.11 12 Trials recruiting 
participants with chronic migraine will come across many 
patients with this dual diagnosis. Current UK guidelines 
published by The National Institute for Health and Care 
Excellence (NICE) recommend the use of BTX-A for 
chronic migraine, but not for high frequency episodic 
migraine, and only when the condition is ‘appropriately 
managed’ for medication overuse.8
The aim of this evidence review was to assess the effects 
of botulinum toxin (BTX) versus placebo or alternative 
active treatment for the prophylaxis of episodic migraine 
or chronic migraine in adults.
This paper is a summary of key aspects from a Cochrane 
review first published in The Cochrane Library 2018, Issue 
6 (see http://www. thecochranelibrary. com/ for informa-
tion).13 Cochrane reviews are regularly updated as new 
evidence emerges and in response to feedback, and 
The Cochrane Library should be consulted for the most 
recent version of the review.
MEthODs
The protocol for this review was published in the 
Cochrane Database of Systematic Reviews in advance of 
the publication of the full review which replaced it. Devia-
tions from the protocol are listed in the full review.13
search strategy
A systematic search of the literature published before 
March 2019 was carried out. We designed a highly sensi-
tive search strategy using methods recommended by the 
Cochrane collaboration to minimise publication bias. 
No date, language or publication status restrictions were 
applied. We used a combination of index terms and free 
text terms for headache, migraine, cephalalgia or hemi-
crania; and botulinum toxin, Botox, onabotulinum toxin, 
Oculinum or clostridium botulinum. Relevant trials 
were identified through electronic searches of Cochrane 
Central Register of Controlled Trials, MEDLINE (see full 
strategy in online supplementary file 1), Embase,  Clinical-
Trials. gov and WHO International clinical trials registry, 
hand-searching reference lists and citation searches 
on key publications and correspondence with all major 
manufacturers of BTX products relevant to this review.
selection criteria
We included randomised, double-blind, controlled trials 
of people over the age of 18 years suffering from migraine 
as defined by any edition of the IHS criteria,11 12 14 or 
meeting reasonable criteria designed to distinguish 
between migraine and tension-type headache. Patients 
with both chronic migraine and episodic migraine were 
included in this review. Medication overuse headache was 
included as these types of participants have been included 
in large and prominent trials in this area. Trials must 
compare BTX (any sero-type) injected into the head and 
neck muscles with placebo injections, clinically relevant 
different dose of same treatment or active preventative 
agent. Trials allowing the use of concomitant preventative 
or rescue treatments were included.
Screening of abstracts and assessment of eligibility of 
full papers were carried out independently in duplicate 
and according to criteria predefined in the peer reviewed 
protocol. If disagreements occurred at any stage, a 
third author considered the available information or if 
necessary the study authors were contacted for clarifica-
tion. When eligibility could not be determined through 
consideration of published materials or contact with trial 
authors the studies were excluded.
Quality assessment
Eligible material was assessed, independently by two 
reviewers for each trial, for methodological quality using 
Cochrane risk of bias methods. Publications were assessed 
on their method of randomisation, blinding and conceal-
ment of allocation, the number of participants lost to 
follow-up, evidence of selective reporting and study size.
We considered the use of funnel plots to assess the risk of 
publication bias but did not carry them out. We made this 
decision because of the small number of studies included 
in the individual meta-analyses and the true heterogeneity 
in the trial design (dose, injection paradigm) and popula-
tions studied (migraine sub-classifications), which would 
make it impossible to draw useful conclusions from the 
plots. Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) tables were created for 
each comparison, this process involves assessment of the 
risk of publication bias for each outcome measure.
Data extraction
Data extraction was carried out independently and in 
duplicate onto forms designed and tested at protocol 
stage. The primary outcome was frequency of migraine 
days per month. Secondary outcomes included: frequency 
of headache days, frequency of migraine attacks, severity 
of migraine, duration of migraine, 50% responder rate, 
global impression scales, quality of life measures and 
adverse event reporting. We used risk ratios (RRs) as the 
preferred statistical output for dichotomous outcomes, 
with 95% CIs. For continuous data, we used mean differ-
ences with 95% CIs. Results with p values lower than 0.05 
were considered to be statistically significant. Twelve 
week time-point data following final round of treatment 
was analysed. We sought data from the first phase for 
any cross-over trials identified. We attempted to contact 
authors and obtain missing data.
statistical analysis
The review authors assessed trial information and base-
line characteristics to identify clinical and methodological 
differences during the data extraction process. If clin-
ical and methodological homogeneity were confirmed, 
we carried out meta-analysis of the data using Review 
Manager (RevMan) V.5.3.15
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Heterogeneity present in doses, injection sites and partic-
ipant populations led to the decision that a random-ef-
fects model should be used for the analysis. RevMan 
implements a version of random-effects meta-analysis that 
is described by DerSimonian and Laird16 and presents 
an estimate of the between-study variance (Tau2) at the 
bottom of each forest plot. We tested for statistical homo-
geneity of pooled estimates of effectiveness using the X2 
test and the I2 statistic, for which a statistically significant 
(p value ≤0.1) value of the X2 test together with I2 value of 
at least 50% indicates heterogeneity.
Within our eligible comparisons, we split data into 
migraine classification subgroups in order to show results 
for chronic migraine, episodic migraine and a mixed 
group for which the diagnosis could not be split.
We planned to use the following subgroups to test for 
variation in the effects of the intervention:
1. Trials including medication overuse headache versus 
trials excluding this type of patient.
2. Different sero-types of BTX (eg, A vs B) and within se-
ro-types (Dysport vs Botox).
3. Different types of agents for the prevention of mi-
graine versus BTX.
4. Accepted and licensed 31 injection pattern versus oth-
er injection patterns used.
At least two trials and 200 participants per group were 
required for any particular subgroup analysis to be carried 
out.
We carried out sensitivity analyses for our primary 
outcome only. Prevailing evidence suggests that smaller 
trials are more likely to report stronger effect estimates 
than large trials.17 18 To assess whether these stronger 
effect estimates reflected the true treatment effect we 
carried out a sensitivity analysis in which we examined the 
effect of removing studies at high risk of bias from study 
size.
We assessed the validity of our findings as well as the 
level of confidence suitable to any estimates of effect 
generated by our analyses using the GRADE approach.19
Patient and public involvement
There was no patient or public involvement in the design 
or reviewing process. However, the final Cochrane manu-
script including a lay summary, which is accessible to the 
public through the Cochrane library, was reviewed by a 
patient representative as part of the editorial process. 
Their feedback was incorporated into the final draft.
rEsults
Description of included studies
The flow of information through the review process is 
given in the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses flow chart in online supple-
mentary file 2. The characteristics of studies included in 
this review are given in online supplementary file 3.
We identified 28 eligible trials, involving a total of 4190 
participants, which were eligible for inclusion in this 
review. Twenty-three of these trials compared BTX-A with 
placebo injections6 7 20–40 and three compared with an 
alternative established oral prophylactic agent.41–43
Five trials, reported in four articles, compared alter-
native doses of BTX-A,26 33–35 all but one of these also 
included a placebo arm26 and one compared with injec-
tions of histamine.44 Due to the paucity of the data, review 
of the dosing studies and the histamine study are included 
as appendices in the Cochrane review and is not repeated 
here.13
The results of the critical appraisal were mixed 
(figure 1). Across all domains poor reporting was an 
issue and in all but attrition bias and study size at least 
50% of trials provided insufficient information to allow 
Figure 1 Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all 
included studies.
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judgments about risk of bias to be made. Only two trials 
were at low risk of bias due to study size (at least 200 
participants per trial arm) and these two trials were also 
at low risk of bias across all other domains.6 7
Sixteen trials were commercially sponsored, 
including the only two trials at low risk from study 
size.6 7 21 22 24–27 32–35 40 41 43
For those trials providing information on the migraine 
diagnosis of their participants the ratio of chronic/
episodic migraine was 1872/1928, leaving 392 included 
participants unclassified and analysed as’ Mixed’. The 
mean age was 42 years and 85% of all participants 
were female. Pregnant women were generally explicitly 
excluded. All included trials used BTX-A, of these 21 
had at least one arm treated with the Botox formula-
tion,6 7 20–24 26 27 30 31 33–35 38 40–44 two used Dysport,25 32 two 
used Prosigne28 31 and one HengLi.29 The range of doses 
administered in trials of Botox was 6 U to 300 U. The trials 
using Dysport administered doses of 80 U up to 240 U in 
treated arms (dose equivalency reported by trial publica-
tions: 2 to 3 U:1 U Botox). HengLi and Prosigne trials 
used doses ranging from 25 U to 96 U (dose equivalency 
reported by trial publications: 1 U:1 U Botox).
Effectiveness versus placebo
Comparison with a placebo group was made in 23 trials 
with 3912 participants.
Meta-analysis of our primary outcome for the four trials 
in chronic migraine which reported it showed that there 
was a reduction of 3.1 days of migraine per month (95% CI 
−4.7 to −1.4) in favour of BTX-A treatment (figure 2). At 
least 60% of the participants in this analysis had medica-
tion overuse headache. The episodic migraine subgroup 
involved only one trial of 418 participants which showed 
no difference in the number of migraine days between 
treated and placebo groups (p=0.49). Insufficient data 
were available to carry out any of the planned subgroup 
analyses on the primary outcome measure. Concern 
about small trial effects caused us to carry out a sensitivity 
analysis. Removal of all chronic migraine trials at high risk 
of bias from study size left just the two PREEMPT trials, 
which gave a more conservative reduction of 2.0 days per 
month (95% CI −2.8 to −1.1, n=1384).
Migraine severity score on a 10 cm visual analogue 
scale, improved by −3.3 cm (95% CI −4.2 to −2.4) more 
with active treatment (figure 3). Only four small trials 
reported meta-analysable data for this outcome. For 
chronic migraine the improvement was −2.7 cm (95% CI 
−3.3 to −2.1, n=75), and for episodic migraine it was 
−4.9 cm (95% CI −6.6 to −3.2, n=34).
A reduction in the number headache days per month 
of 1.9 days (95% CI −2.7 to −1.0, two trials, n=1384) in 
favour of BTX-A treatment was also seen. However data 
for number of migraine attacks from six trials of both 
chronic migraine and episodic migraine participants 
(n=2004) showed no significant between group differ-
ence (p=0.30). Duration of migraine in hours was fully 
reported by only one trial showing a greater reduction 
of −5.1 hours (95% CI −6.2 to −4.0) for 102 chronic and 
episodic migraine participants. A further four trials 
with 420 participants reported no significant differ-
ence between groups for this outcome. Global assess-
ment measures and quality of life measures were poorly 
reported and it was not possible to carry out statistical 
analysis of these outcome measures.
Effectiveness of btX versus oral prophylactic agents
Three trials with 178 participants compared Botox injec-
tions with oral prophylactic agents using double dummy 
techniques. Two trials compared 100 U fixed dose plus 
optional dose of up to 100 U of Botox with topiramate 
maximum dose 200 mg/day.42 43 The third trial compared 
treatment with up to 100 U Botox with sodium valproate 
250 mg twice daily.41 Fourteen of the 178 participants 
had episodic migraine, all other participants had chronic 
migraine. Where meta-analysis was possible we pooled 
data from these three trials as there were insufficient 
data to allow us to explore comparisons with individual 
drug types or effects on chronic migraine and episodic 
migraine populations.
The primary outcome, number of migraine days per 
month was recorded in only one of the active comparison 
Figure 2 Comparison of BTX-A versus placebo in relation to number of migraine days per month. BTX-A, botulinum toxin type 
A. 
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trials. The trialists reported that there was no statistically 
significant difference between treatment with BTX-A and 
topiramate for this outcome.43
The number of headache days per month was recorded 
in two trials. No difference in number of headache days 
per month between treatment with BTX-A and sodium 
valproate was reported (p=0.55).35 No data were reported 
but it was stated that there was also no statistically signif-
icant difference between BTX-A and topiramate treated 
groups.42 A 5-point scale was used to compare the effect 
of BTX-A with alternative agents in two trials, Blumenfeld 
et al. reported no significant difference and Mathew et 
al. reported within group analysis only.41 43 Number 
of migraine attacks and duration of migraine were not 
reported by any trial. No difference between BTX-A and 
topiramate was stated for use of rescue medications.43
Of all the secondary outcome measures, data for 
meta-analysis were available only for the Migraine 
Disability Assessment (MIDAS) scores. Results of this 
showed no significant difference in change scores 
between the established drug treatments and injection 
with Botox (p=0.80, two trials, n=101).
safety
BTX-A had an RR of treatment related adverse events 
of twice that seen for placebo (2.2, 95% CI 1.7 to 2.8, six 
Figure 3 Comparison of BTX-A versus placebo in relation to severity of migraine measured on a 10 cm visual analogue 
scale. BTX-A, botulinum toxin type A. 
Figure 4 Comparison of BTX-A versus placebo in relation to treatment related adverse events. BTX-A, botulinum toxin type A. 
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trials, n=2839) (figure 4). All of these events were tran-
sient and non-serious, the most common being blepha-
roptosis, muscle weakness, injection site pain and neck 
pain.
Compared with oral treatments, BTX-A showed a 
reduced RR of treatment related adverse events of 0.76 
(95% CI 0.59 to 0.98, two trials, n=73). There was also 
difference in favour of BTX-A in the RR of withdrawing 
due to adverse events of 0.28 (95% CI 0.10 to 0.79, I2=0%) 
which is a RR reduction of 72%.
A low withdrawal rate of 3% for BTX-A was generated 
using data from all those trials treating with more than 
one injection cycle irrespective of the type of comparison 
arm.
Quality of the evidence
The quality of the evidence assessed using GRADE 
methods was varied but mostly low and very low; the 
primary outcome measure was low and very low quality 
evidence for the placebo and active control comparisons 
respectively. Small trial size, high risk of bias and unex-
plained heterogeneity were common reasons for down-
grading the quality of the evidence. All judgements and 
reasons for gradings are given in online supplementary 
file 4 and 5.
DIsCussIOn
Evidence was identified to support the use of injections 
of BTX-A into the head and neck muscles, to reduce the 
number of migraine days experienced per month. Mean 
frequency of migraine days was significantly reduced 
by 3 days per month more by BTX-A treatment than by 
placebo, but this result was revised to 2 days per month as 
a result of sensitivity analyses. All patients included in this 
analysis had chronic migraine and so had a high baseline 
frequency with an average of 20 days per month quoted 
by the two largest trials in the analysis.6 7 For patients 
with chronic migraine, likely to be refractory to first and 
second line treatment, a 2 to 3 day improvement may well 
represent a meaningful difference. BTX-A groups also 
fared better than placebo in the frequency of headache 
days by 2 days per month. Severity of migraine measured 
on a visual analogue scale was improved by 3 cm for 
chronic migraine and 5 cm for episodic migraine on a 
10 cm scale. Though these results were from few small 
trials and the estimate is considered to be low quality 
evidence, the differences in severity scores were in excess 
of the minimal clinically important difference of 1.2 cm 
determined by Kelly45 and indicate that the treatment 
may be reducing the impact of each migraine attack. In 
contrast to this no significant difference from placebo was 
observed for frequency of migraine attacks. Patient and 
clinician reported global assessment scales and quality of 
life scales were underused and when they were incorpo-
rated into trials they were poorly reported, so no aggrega-
tion of data of this type comparing investigative treatment 
with placebo was possible in this review.
It was not possible to carry out any analysis on head-
ache diary outcomes or severity measures for head-to-
head comparisons between BTX-A and other established 
agents due to lack of available data. MIDAS scores for 101 
patients from two small trials, one comparing Botox with 
topiramate and one with sodium valproate were available 
and these showed no significant between group differ-
ence (p=0.8).
Trials included in this review commonly state that BTXs 
have good safety profiles and the evidence from the 23 
trials included in this review which reported adverse 
events in some form support those assertions. Although 
an increased risk of experiencing treatment related 
adverse events was found for the BTX-A treated group 
compared with placebo, the event types were non-serious 
and transient.
A relative risk reduction (RRR) of 24% in treatment 
related adverse events in favour of BTX-A was found 
when comparing with topiramate and sodium valproate 
in two trials. These two trials found an RRR in favour of 
BTX-A of 72% for withdrawal rate due to adverse events. 
Percentage withdrawals due to adverse events for all of 
those trials included in this review which used more 
than one round of BTX-A injections, irrespective of the 
comparison arm type, was 3%. The data sets for the direct 
comparisons with other prophylactic agents were small, 
but the relationship is supported by the indirect compar-
ison of this percentage with published rates of 20% for 
topiramate and 12% for sodium valproate.46 47 This result 
suggests that patients tolerate this treatment better than 
the oral alternatives.
Reporting was generally poor, with only six of 28 
trials reporting data on our primary outcome in a 
usable format, and an additional five providing data for 
frequency of migraine attacks. These two outcomes are 
recommended as primary outcomes by the trial guide-
lines produced by the IHS and should be fully reported 
to allow individual trials to be placed in the context of 
the totality of the evidence.48 A large proportion of the 
recorded data were missing from the published reports 
of our included trials. Failure to fully report data in trial 
publications led to problems throughout the meta-anal-
ysis and greater confidence in the conclusions would have 
been possible if all trials that recorded our outcomes of 
interest had fully reported them.
Prophylactic treatments for migraine aim to reduce 
the frequency, duration and/or the intensity of attacks. 
Frequency of migraine attacks was commonly used as 
the primary outcome particularly in studies carried out 
before the publication of the PREEMPT trials. Use of 
this measure may mask an important improvement in 
symptoms seen in the form of shorter and less intense 
migraine attacks. Use of the more sensitive measures, 
number of days or hours spent with migraine per month 
coupled with a measure of intensity, may enable detec-
tion of such changes and could be particularly relevant 
to episodic migraine patients for whom attacks may be 
shorter at baseline. Another problem with focusing on 
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this outcome measure was the failure generally to define 
what was meant by a migraine attack, and therefore, the 
likelihood of variation in the definitions used across the 
trials.
Neither efficacy nor safety data were available for 
long-term treatment with BTX. The longest treatment 
period in any of the studies included in this review was 
three treatments with 12 weeks between treatments, so 
we cannot know the implications of treating patients with 
BTX over a period longer than 9 months.
Most trials did not report whether or not they had 
included patients with medication overuse symptoms and 
those that did stated they had largely excluded medica-
tion overuse patients. Pooled data for the two PREEMPT 
trials for the chronic migraine plus medication overuse 
subgroup (n=906) showed that the difference between 
groups for both migraine and headache day frequencies 
was 2 days (p<0.001) in favour of treatment with BTX.49 
The medication overuse subgroup result falls within the 
CIs of the pooled estimate generated by this review for 
the same outcome measure in combined populations 
with and without medication overuse headache. It would 
appear from these data that the inclusion of patients with 
medication overuse does not change the effectiveness of 
BTX for prophylactic treatment of migraine.
COnClusIOns
We have data which suggest that BTX effectively reduces 
the duration and severity of migraines in sufferers. There 
are however question marks over the quality of the 
evidence. Efficacy measures were commonly reported as 
showing non-inferiority of BTX to topiramate and sodium 
valproate and the withdrawal rate from BTX is much 
lower than that for first line prophylactic treatments for 
migraine. So should we be using more BTX?
It is currently recommended by NICE guidance that 
medication overuse headache should be addressed before 
treatment with BTX but trial data suggests it is efficacious 
in chronic migraine patients with untreated medication 
overuse headache. So although treatment of medication 
overuse headache is good practice, perhaps it should 
not be a requirement before prescription of BTX. NICE 
recommends the use of BTX to treat chronic migraine 
that has not responded to at least three prior pharma-
cological prophylaxis therapies. The confidence in the 
effectiveness of these drugs is arguably no greater than 
that for BTX and patients seem better able to tolerate 
BTX.4 5 46 47 If, as is suggested by trial data, BTX has the 
equivalent efficacy to other agents but lower withdrawal 
rates, then if it were not for the higher cost, BTX would 
likely be recommended as an earlier preventative treat-
ment for chronic migraine.
The difference between chronic and episodic migraine 
diagnoses is arbitrary and so there is no pathophysiolog-
ical reason that treatment with BTX would be efficacious 
in people with 15 days of headache per month and ineffi-
cacious in people with 14 days of headache per month in 
a stepwise fashion. The treatment may well be useful for 
episodic migraine, particularly in high frequency episodic 
migraine, but data is lacking.
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